The Safety and Efficacy of Hydroxyapatite Repair of Cholesteatoma Skull Base Defects

Abstract

AbstractObjectiveTo investigate the possibility of hydroxyapatite as a safe and effective alternative to currently used bioavailable materials for repair of tegmen defects and labyrinthine fistulas in the setting of cholesteatoma.Study DesignRetrospective study.SettingTertiary‐level‐care hospital.MethodsElectronic medical records of patients 18+ years undergoing cholesteatoma‐removal surgery between 2013 and 2022 were reviewed.ResultsTwenty‐two patients diagnosed with cholesteatoma who underwent repair of either a tegmen defect or labyrinthine fistula using hydroxyapatite were evaluated. There were 17 canal wall up (CWU) and 5 canal wall down (CWD) surgeries. The cholesteatoma recidivism rate was 18.2% (n = 4) and the recurrence rate was 4.5% (n = 1). To ensure that these rates were similar to cholesteatoma‐removal surgeries in which hydroxyapatite was not used, a 22 age, gender, and operative technique‐matched cohort was evaluated. For patients with CWU surgeries, the rate of recurrence and recidivism were identical between both cohorts (0% and 23.5%, respectively; P = 1 for both). While in CWD surgeries, there was a nonstatistically significant difference in the recurrence as there was only 1 patient with recurrence in the hydroxyapatite group (P = 1). Three (13.5%) patients in the hydroxyapatite group had a local infection and 1 (4.5%) had a subacute mastoid infection. All patients with semicircular canal fistulas had consistent bone lines on postoperative audiograms, with no worsening sensorineural hearing loss.ConclusionIn our cohort, hydroxyapatite was safe and successful in repairing skull base defects and inner‐ear fistulas in the setting of cholesteatoma with a low rate of postoperative infection and no evidence of a higher rate of cholesteatoma recurrence. Further studies are needed to assess population generalizability.